NCT06912477Recruiting
Endothelial Dysfunction for Prognosis In Patients With preeClampSia
Systematic Evaluation of Endothelial Dysfunction as a Prognostic Marker for Outcomes in Women With Preeclampsia
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
Preeclampsia is a pregnancy-specific hypertensive disorder and can progress rapidly to severe adverse outcomes affecting both the mother and the fetus. Endothelial and microcirculatory dysfunction mediate systemic preeclampsia-related organ dysfunctions. Changes in endothelial and vascular function in preeclampsia have been demonstrated through reduced flow-mediated vasodilation as a result of reduced availability of nitric oxide, which potentially persists up to several years postpartum. Hyperspectral imaging is a new innovative technology that allows to assess the peripheral microcirculation and perfusion non-invasively and contactless, but has never been evaluated in the context of preeclampsia before. This EPICS project (Endothelial dysfunction for Prognosis In patients with preeClampSia) is a prospective observational study and aims to investigate hyperspectral imaging as a new potential diagnostic and prognostic marker in preeclampsia.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 385 (estimated)
- First submitted
- 25 Mar 2025
- Start date
- 8 May 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Heidelberg University
- Diseases
- High blood pressure
- NCT number
- NCT06912477
What you commit to
- Study type: Observational
- Planned participants: 385
- From 8 May 2025 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- Laboratory changes in LDH, creatinine, or platelets due to other causes (e.g., isolated thrombocytopenia, e.g., immune thrombocytopenia, carcinoma)
Other
- Lack of consent
- Language barrier
- Dark to very dark skin type
- Severe fetal chromosomal/genetic/structural anomalies
Who the study is looking for
- singleton pregnancies
- Age ≥ 18 years
- Patient's ability to provide consent
- written informed consent
Age in the registry: 18 years to - · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heidelberg University Hospital, Department of Gynecology and Obstetrics Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.